JP2007522223A - 制御放出配合物 - Google Patents

制御放出配合物 Download PDF

Info

Publication number
JP2007522223A
JP2007522223A JP2006553213A JP2006553213A JP2007522223A JP 2007522223 A JP2007522223 A JP 2007522223A JP 2006553213 A JP2006553213 A JP 2006553213A JP 2006553213 A JP2006553213 A JP 2006553213A JP 2007522223 A JP2007522223 A JP 2007522223A
Authority
JP
Japan
Prior art keywords
composition
morphine
nasal
chitosan
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006553213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522223A5 (https=
Inventor
マイケル モシュマン
フレッド マーメルスタイン
Original Assignee
イノヴェイティヴ ドラッグ デリヴァリー システムズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノヴェイティヴ ドラッグ デリヴァリー システムズ インコーポレイテッド filed Critical イノヴェイティヴ ドラッグ デリヴァリー システムズ インコーポレイテッド
Publication of JP2007522223A publication Critical patent/JP2007522223A/ja
Publication of JP2007522223A5 publication Critical patent/JP2007522223A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006553213A 2004-02-10 2005-02-09 制御放出配合物 Pending JP2007522223A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/776,333 US20050175679A1 (en) 2004-02-10 2004-02-10 Controlled release formulations
PCT/US2005/004163 WO2005077346A1 (en) 2004-02-10 2005-02-09 Controlled release formulations

Publications (2)

Publication Number Publication Date
JP2007522223A true JP2007522223A (ja) 2007-08-09
JP2007522223A5 JP2007522223A5 (https=) 2008-04-03

Family

ID=34827359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553213A Pending JP2007522223A (ja) 2004-02-10 2005-02-09 制御放出配合物

Country Status (10)

Country Link
US (2) US20050175679A1 (https=)
EP (1) EP1720532A1 (https=)
JP (1) JP2007522223A (https=)
KR (1) KR20060135769A (https=)
AU (1) AU2005212355B2 (https=)
BR (1) BRPI0506630A (https=)
CA (1) CA2555882A1 (https=)
IL (1) IL177328A0 (https=)
MX (1) MXPA06009094A (https=)
WO (1) WO2005077346A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031551A (ja) * 2011-08-25 2019-02-28 イヴォーク ファーマ，インク 女性胃不全麻痺に関係する症状の処置
US11020361B2 (en) 2008-12-22 2021-06-01 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007083984A1 (en) 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
KR100766820B1 (ko) 2006-01-23 2007-10-17 광주과학기술원 단백질 또는 펩타이드의 경점막 운반 시스템
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
JP5258315B2 (ja) * 2007-05-25 2013-08-07 ロート製薬株式会社 フルニソリド含有粘膜適用組成物
JP7217071B2 (ja) * 2019-09-30 2023-02-02 エルジー・ケム・リミテッド 高吸水性樹脂およびその製造方法
EP4230206A1 (en) * 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04221313A (ja) * 1990-03-27 1992-08-11 Warner Lambert Co 副鼻腔性頭痛の処置
JP2000507241A (ja) * 1996-03-20 2000-06-13 パル スヴェードマン 経皮デバイス
JP2002519318A (ja) * 1998-06-26 2002-07-02 エルデイエス・テクノロジーズ・インコーポレーテツド 鼻および肺送達のためのコルチコステロイドを含有する水性組成物
JP2003512380A (ja) * 1999-10-20 2003-04-02 ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド 化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5508282C1 (en) * 1993-05-17 2001-01-23 Tulin Silver Jeffrey Composition and method for treating acute or chronic rhinosinusitis
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JP4137179B2 (ja) * 1994-03-30 2008-08-20 ジーエス ディベロップメント エービー 生物付着性物質としての脂肪酸エステルの使用
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
HRP20010926A2 (en) * 1999-06-16 2003-04-30 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04221313A (ja) * 1990-03-27 1992-08-11 Warner Lambert Co 副鼻腔性頭痛の処置
JP2000507241A (ja) * 1996-03-20 2000-06-13 パル スヴェードマン 経皮デバイス
JP2002519318A (ja) * 1998-06-26 2002-07-02 エルデイエス・テクノロジーズ・インコーポレーテツド 鼻および肺送達のためのコルチコステロイドを含有する水性組成物
JP2003512380A (ja) * 1999-10-20 2003-04-02 ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド 化合物

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020361B2 (en) 2008-12-22 2021-06-01 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11628150B2 (en) 2008-12-22 2023-04-18 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11813231B2 (en) 2008-12-22 2023-11-14 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US12194009B2 (en) 2008-12-22 2025-01-14 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US12194008B2 (en) 2008-12-22 2025-01-14 Evoke Pharma, Inc. Nasal formulations of metoclopramide
JP2019031551A (ja) * 2011-08-25 2019-02-28 イヴォーク ファーマ，インク 女性胃不全麻痺に関係する症状の処置
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
US12377064B2 (en) 2016-12-15 2025-08-05 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis

Also Published As

Publication number Publication date
AU2005212355B2 (en) 2010-06-17
MXPA06009094A (es) 2007-02-02
KR20060135769A (ko) 2006-12-29
IL177328A0 (en) 2006-12-10
CA2555882A1 (en) 2005-08-25
US20050175679A1 (en) 2005-08-11
EP1720532A1 (en) 2006-11-15
AU2005212355A1 (en) 2005-08-25
US20080221144A1 (en) 2008-09-11
BRPI0506630A (pt) 2007-05-08
WO2005077346A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
US20240261278A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US8889176B2 (en) Method of managing or treating pain
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
US20080221144A1 (en) Controlled Release Formulations
KR20090033903A (ko) 향상된 흡수를 갖는 경점막 전달 장치
US12514854B2 (en) Drug products for intranasal administration and uses thereof
KR20240165490A (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
EP3927321B1 (en) Naloxone formulations for sublingual and/or buccal administration
US20240408004A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
CA3124202A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
KR20030000397A (ko) 아포모르핀 비강투여 제제 및 그의 제조방법
HK1198958B (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
HK1168539A (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120409